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The yield of preoperative PET/CT (PET/CT) for regional and distant metastases for thin/intermediate thickness melanoma is low.
Objective of this study is to determine if PET/CT performed for T4 melanomas helps guide management and alter treatment
plans. Methods. Retrospective cohort of 216 patients with T4 melanomas treated at two tertiary institutions. Fifty-six patients met
our inclusion criteria (T4 lesion, PET/CT and no clinical evidence of metastatic disease). Results. Fifty-six patients (M: 32, F: 24)
with median tumor thickness of 6 mm were identiﬁed. PET/CT recognized twelve with regional and four patients with metastatic
disease. Melanoma-related treatment plan was altered in 11% of the cases based on PET/CT ﬁndings. PET/CT was negative 60%
of the time, in 35% of the cases; it identiﬁed incidental ﬁndings that required further evaluation. Conclusion. Patients with T4
lesions, PET/CT changed the treatment plan 18% of the time. Regional ﬁndings changed the surgical treatment plan in 11% and
the adjuvant plan in 7% of our cases due to the ﬁnding of metastatic disease. Additionally 20 patients had incidental ﬁndings that
required further workup. In this subset of patients, we feel there is a beneﬁt to PET/CT, and further studies should be performed
to validate our ﬁndings.
1.Introduction
Cutaneous malignancies constitute one of the most com-
monly diagnosed cancers in the United States (USA), com-
prising more than half of all cancers diagnosed each year
[1]. Cutaneous melanoma represents approximately four
percent of all skin cancers diagnosed each year, but accounts
for approximately 75% of skin-cancer-related deaths. In the
USA in the year 2010, 68,130 new cases of melanoma were
diagnosed, with 8,700 patients dying of the disease [2].
The incidence is increasing dramatically. The age-adjusted
incidence of invasive melanoma in the USA increased
from approximately four per 100,000 to 18 per 100,000 in
white males between 1973 and 1998 [3]. The incidence of
cutaneous melanoma continues to increase dramatically, in-
creasinginmenmorerapidlythananyothermalignancy,and
inwomenmorerapidlythananyothermalignancyexceptfor
lung cancer [4]. The lifetime risk of developing melanoma
for someone born in the USA in the year 2000 is 1 in 41 for
m e na n d1i n6 1f o rw o m e n[ 3].
18-Fluorodeoxyglucose (18F-FDG) positron emission to-
mography/computedtomography(PET/CT)isausefulfunc-
tionalimagingmodalityforthestagingofmelanomaandhas
a potential role in assessing response to therapy. Wahl et al.
[5]a n dK e r n[ 6] demonstrated that radiolabeled glucose an-
alogs were preferentially taken up in murine melanomas and
human melanoma xenografts, setting forth the rationale for
the potential use of FDG in patients with melanoma.
Numerous studies have shown that PET/CT is not useful
in the initial staging of thin and intermediate thickness pri-
mary cutaneous melanoma when there is no clinical evi-
denceoflocalordistantmetastaticspread[7–10].Thereason
for this is the small size/volume of most nodal metas-
tases combined with the low prevalence of nodal disease2 Dermatology Research and Practice
in patients with early primary melanomas [11]. PET/CT
generally can only detect lesions approximately 8mm in
diameter. Friedman and Wahl recommend using PET/CT
for evaluating patients with cutaneous melanoma who ﬁt
into one of the four following categories: (1) individuals
with a high risk for distant metastases based on extent
of locoregional disease, (2) patients with ﬁndings that are
suspiciousfordistantmetastases,(3)individualswithknown
distant tumor deposits who still stand to beneﬁt from
customized therapies if new lesions are discovered or treated
lesions regress, and (4) patients at high risk for systemic
relapse who are considering aggressive medical therapy [12].
The objective of our study was to determine if preoperative
PET/CTperformedforT4melanomashelpedguidemanage-
ment and alter the treatment plan.
2. Methods
A retrospective cohort study was performed at two tertiary
referralcenters,FoxChaseCancerCenterandThomasJeﬀer-
son University Hospital. Institutional review board approval
was obtained from both institutions. Inclusion criteria were
as follows: patients with the histopathologic diagnosis of a
primary cutaneous melanoma with a T4 (tumor thickness
greater than 4mm) lesion based on the AJCC staging system
[13], patients who had a preoperative PET/CT performed
as part of their staging workup, and no clinical evidence of
locoregional or distant metastatic disease. We identiﬁed 216
patients with T4 melanomas treated between January 2003
andJanuary2009.Fiftysixpatientsmetourinclusioncriteria
of having a T4 lesion with a preoperative PET/CT and no
clinical evidence of regional or distant metastatic disease.
Medical records were reviewed, and patient demographics,
characteristics of their primary tumor, and ﬁndings from
PET/CT studies were analyzed. Any deviation from the
preoperativeplan(changeinthesurgicalprocedure,addition
studies for the workup of incidental ﬁndings, or additional
consultations with the medical or radiation oncologist) that
occurred due to the results of the staging PET/CT was con-
sidered as a change in the treatment plan. A true positive
PET/CT for regional disease and metastatic disease was
deﬁnedbythepresenceofmalignantdiseaseintheﬁnalpath-
ology specimen and during the workup of metastatic disease
(ultrasound-guided or CT-guided biopsies of the metastatic
foci).
The PET/CT scans were obtained according to the fol-
lowing standard protocol in both institutions: all patients
were asked to fast for at least 4 hours before the study. After
measurement of blood glucose level and conﬁrming it is
below 200, the patient was given an I.V. injection of approx-
imately 15mCi of 18F-FDG as standard dose. After a delay
of 1 to 2 hours, the patient voided, and the PET/CT scan
was performed on a GE Discovery LS PET/CT Scanner or
a Siemens Biograph 16 PET/CT Scanner from the vertex of
the head down to feet for all patients to cover the entire skin
surfac e.TheCTimagesw er eac quir edinhelicalmodeduring
normal breathing and were used for registration with the
PET images and for applying attenuation correction.
For Discovery LS (from 2003 to 10/2010), the CT
scan acquisition parameters were 140kVp, 90mA, 0.8s per
rotation, slice thickness of 5mm, 0.75 pitch, and interval of
4.25mm.TheﬁeldofviewforPETandCTimageswas50cm
diameter .ThePETscanswer eac quir edfor6or7minutesper
bed position in 2D mode with a single-slice overlap and were
reconstructed using ordered subsets expectation maximiza-
tion (OSEM) algorithm with 28 subsets and 2 iterations
usingmanufacturer-suppliedsoftware.ThePETsystemhasa
2-dimensionaltransaxialresolutionof4.7mmfullwidthhalf
maximum (FWHM) at 1cm radius and 5.2mm at 10cm
radius.
For Siemens Biograph (from 10/2010 to present), the
CT scan was acquired using CareDose4D with the following
acquisition parameters: 130 kVp, reference mAs of 100, 0.6
s per rotation, 5mm slice thickness, pitch of 1.0, and 70cm
diameter ﬁeld of view. The PET scan was acquired for 2 to 3
minutes per bed position in 3D mode with 16-slice overlap
andwasreconstructedusingTrueXalgorithmwith21subsets
and 2 iterations, with 63cm diameter ﬁeld of view using
manufacturer-supplied software. The PET system has a 2-
dimensional transaxial resolution of 4.4mm FWHM at 1cm
radius and 4.6mm at 10cm radius.
ThePETreconstructionincludedcorrectionsforrandom
and scatter. Attenuation correction was applied based on the
low-dose CT to reduce radiation exposure to the patients. All
images were corrected for body weight, dose administered,
and radioactive decay and displayed on an eNTEGRA or
Xeleris workstation for GE scanner or multimodality work-
placeforSiemensscannerwithaninitialstandardizeduptake
value (SUV) gray scale of 0 (white) to 5 (black).
The PET scans were reviewed to determine the length of
the abnormality with an SUV of 2.5 as cutoﬀ value to de-
lineate the tumor extent. The maximum SUV within the tu-
mor volume was also determined by manufacturer build-in
computer algorithm.
The SUV values are comparable between the two scan-
ners with cross-calibration performed by manufacturer-
trained ﬁeld engineers and our in-house medical physicist.
There are many studies displayed and reviewed in both sys-
tems during the transition period from GE to Siemens scan-
ner.
3. Results
Of the 56 patients, 32 (57%) were male and 24 (43%) were
female. The mean age of the patients in our study was 67
years(range,26to89years),andthemediantumorthickness
was 6mm (range, 4.1mm to 40mm). Tumor ulceration was
identiﬁed in 61% of the cases (n = 34) and satellitosis in
25% (n = 25) of the cases. Fifty percent of the melanomas
were located in the extremities (n = 28), 29% in the trunk
(n = 16), and 21% in the head and neck region (n = 12)
(Table 1).
Preoperative PET/CT identiﬁed twelve (21%) patients
with regional disease and four (7%) patients with metastatic
disease (Figures 1, 2,a n d3). Preoperative PET/CT changed
the treatment plan 18% of the time. Regional ﬁndingsDermatology Research and Practice 3
Table 1: Demographics.
Patient characteristics
Patients (n)5 6
Male: female (n)3 2 : 2 4
Age (mean, range) 67 yrs,
(26–89 yrs)
Tumor characteristics
Median tumor thickness 6 mm,
(4.1–40mm)
Mean tumor thickness 9mm
Tumor ulceration (n)3 4
Satellitosis (n)2 5
Location of the melanoma
(n, % of cases)
Trunk 16 (29%)
Extremities 28 (50%)
Head and neck 12 (21%)
Figure 1: Lymph node uptake.
changed the surgical treatment plan in 11% of our cases, and
systemic chemotherapy (temozolomide) was added in 7% of
our cases due to the ﬁnding of metastatic disease (Table 2).
Six patients (11%) proceeded directly to therapeutic lymph
node dissection due to the preoperative PET/CT ﬁndings,
thereby eliminating the need for sentinel lymph node biopsy
(SLNB). In all six cases, the reason for performing the
therapeutic lymph node dissection rather than the SLNB was
thedepthoftheprimarymelanoma,thepresenceofclinically
detectedlymphadenopathy,andthepresenceofPET/CTavid
lymph nodes (patient number six did not undergo SLNB do
to clinically evident disease in the inguinal region). Based
on the ﬁndings of metastatic disease on the preoperative
PET/CT, four patients were presented in a multidisciplinary
tumor board for discussion of systemic chemotherapy and
the possibility of having been enrolled into a clinical trial.
Patient number three in Table 2 with metastatic disease in
theliverunderwentoperative intervention withrightaxillary
dissection for debulking and palliation only not for curative
intent.
PET/CT was negative 60% (n = 33) of the time, and in
35% (n = 20) of the cases, it identiﬁed incidental ﬁndings
Figure 2: Liver and vertebral uptake.
Figure 3: Liver uptake.
that required further evaluation (mediastinal lymphadenop-
athy, lung, colon, and thyroid lesions). Three patients with
positive ﬁndings on preoperative PET/CT were found to
have incidental ﬁndings not related to their melanoma
and form part of the 20 patients who were reported to
have incidental ﬁndings. The sensitivity and speciﬁcity of
PET/CT for identifying regional metastatic disease were
40% and 90%, respectively. The sensitivity and speciﬁcity
for identifying distant metastatic disease were 100% and
94%, respectively (Table 3). The combined sensitivity and
speciﬁcity for identifying regional and metastatic disease
were 45% and 88%, respectively (Table 3). The positive
predictive value (PPV) and negative predictive value (NPV)
of PET/CT for identifying regional metastatic disease were
86% and 50%, respectively. Tables 4, 5,a n d6 show the
2×2 tables that were used to calculate the sensitivities and
speciﬁcities previously sited. The positive predictive value
(PPV) and negative predictive value (NPV) of PET/CT
for identifying distant metastatic disease were 57% and
100%, respectively. The combined positive predictive value
(PPV) and negative predictive value (NPV) of PET/CT for
identifying regional and metastatic disease were 82% and
55%. Of the 23 patients (48%) that had a positive SLNB, six
(26%) had avid lymph nodes on PET/CT.4 Dermatology Research and Practice
Table 2 :A l t e r e ds u r g i c a lp l a nb a s e do nP E T .
Diagnosis Operative plan
Patient Pre-PET scan Post-PET scan Pre-PET scan Post-PET scan
1 Back melanoma Axillary uptake WLE + SLNB WLE + L SLB +R LND
2 Back melanoma Axillary uptake WLE + SLNB WLE + bilateral LND
3 Back melanoma L Hilar, R axillary,
and liver uptake WLE + SLNB WLE + R LND
4 Forehead
melanoma
Submandibular,
periauricular
uptake
WLE + SLNB WLE + parotidectomy + R
MRND
5 Leg melanoma Inguinal node
uptake WLE + SLNB WLE + LND
6 Foot melanoma uptake at calf WLE + SLNB WLE + R LND + excision
of In transit lesion
WLE = wide local excision; SLNB = sentinel lymph node biopsy; LND = lymph node dissection; MRND = modiﬁed radical neck dissection; R = right;L = left.
Table 3: Sensitivity and speciﬁcity.
Sensitivity Speciﬁcity
Combined 0.5 0.88
Regional 0.4 0.9
Mets 1.0 0.94
Table 4: 2 × 2 Table of PET/CT with regional metastatic disease.
+ PET/CT with
regional Disease
Conﬁrmed
regional disease
Frequency percent
(a) Disease present (b) No Disease Total
(a) Positive test 14 2 16
23.08 3.85 26.92
(b) Negative test 19 21 40
34.62 38.46 73.08
Total 33 22 56
57.69 42.31 100.00
Table 5: 2 × 2 Table of PET/CT with distant metastatic disease.
+ PET/CT with
metastatic disease
Conﬁrmed
metastatic disease
Frequency percent
(a) Disease present (b) No Disease Total
(a) Positive test 53 8
7.27 5.45 12.73
(b) Negative test 04 8 4 8
0.00 87.27 87.27
Total 55 1 5 6
7.27 92.73 100.00
4. Discussion
The staging of patients with melanoma is a crucial step in the
sequence of events that leads to instituting appropriate man-
agement. Multiple studies have shown that PET/CT has no
Table 6: 2 × 2 Table of PET/CT with combined regional and
distant metastatic disease.
+ PET/CT regional
and metastatic
disease
Conﬁrmed
regional and
metastatic disease
Frequency percent
(a) Disease present (b) No disease Total
(a) Positive test 15 3 18
25.45 5.45 30.91
(b) Negative test 17 21 38
30.91 38.18 69.09
Total 32 24 56
56.36 43.64 100.00
role in the initial staging of thin and intermediate thickness
melanomas in the absence of signs or symptoms suggestive
of distant disease [11, 13, 14]. One of the ﬁrst articles to
suggest that PET/CT was not as sensitive for staging of
regional nodes in patients with cutaneous melanomas came
from a prospective trial containing 70 patients with primary
melanomas (>1.0mm in thickness) and four patients with
recurrent melanoma who underwent PET/CT and sentinel
lymph node (SLN) biopsy. The biopsy results were used
as a gold standard for regional lymph node metastases.
PET/CT scans found two true positives, 71 true negatives,
0 false positives, and 16 false negatives for a sensitivity of
11% and speciﬁcity of 100%. In this study, Wagner et al.
concluded that PET/CT is an insensitive indicator of occult
regional lymph node metastases in patients with melanoma
because of the minute tumor volumes in this population
[11]. In another study, Belhocine et al. [15] showed that
of six histologically positive SLNs in patients with clinically
localized disease, PET/CT identiﬁed only one metastatic
focus in an SLN that was greater than one centimeter [16].
Acland et al. found that in 50 patients who underwent SLN
biopsy for melanomas that were pathologically greater than
1mm in thickness or invading lymphatic’s, PET/CT failed
to identify all 14 positive SLNs [17]. Another study of 609
patients staged using PET/CT (pooled from several studies),
38 patients (6%) had abnormal uptake outside the primaryDermatology Research and Practice 5
Table 7: Sentinel Lymph Node Biopsy (SLNB).
Yes No
SLNB 48 (86%) 6 (11%)
Positive SLNB 23 (48%) 25 (52%)
Positive SLN and a positive node on PET/CT 6 (26%) 17 (74%)
site or regional nodes, but only 1 had a true melanoma me-
tastasis [16].
In our study of T4 melanoma, 12 (21%) patients had
regional metastatic disease, and four (7%) patients had
distant metastatic disease that was identiﬁed with preoper-
ative PET/CT. The diagnostic yield of preoperative PET/CT
for regional [8, 9, 11, 18–21] and distant metastases [18–
22] for thin and intermediate thickness melanoma is low. A
previous study from our institution retrospectively reviewed
83 patients with intermediate thickness melanoma who
underwent SLN biopsy, of which 45% had preoperative
PET/CT. Only two patients from this study with positive
SLNB were found to have avid lymph nodes on preoperative
PET/CT (Table 7). This study did not support the routine
use of PET/CT for patients undergoing SLNB for melanoma
[23]. Our study showed that the sensitivity and speciﬁcity
of PET/CT for identifying regional metastatic disease were
40% and 90%, respectively. In the literature, the sensitivity
and speciﬁcity of PET/CT for identifying regional metastatic
disease have varied from 8% to 100% and 84% to 100%,
respectively [8, 9, 11, 17, 24–26]. Studies performed in
the 1990s have much better sensitivities compared to more
recent ones, and this might be due to the small number
of cases reported in the earlier studies, and possible selec-
tion/inclusion bias. The sensitivity and speciﬁcity of PET/CT
foridentifyingdistantmetastaticdiseaseintheliteraturehave
rangedfrom78%to100%and22%to87%,respectively[18–
22].Inourstudy,thesensitivityandspeciﬁcityforidentifying
distant metastatic disease were 100% and 94%, respectively.
PET/CT ﬁndings did contribute important information that
led to the modiﬁcation of the original treatment plan and
discovered an incidental ﬁnding in 20 cases that required
further evaluation.
Some limitations to this study must be considered. This
study represents a retrospective analysis from a cohort of pa-
tientsfromtwotertiaryinstitutes,andthepossibilityofselec-
tion bias always exists. Also due to the small sample size, we
cannot make deﬁnitive conclusions on the potential beneﬁts
that PET/CT has on the initial evaluation of cutaneous mela-
noma.
Our study suggests that patients with thick melanomas
can beneﬁt from a preoperative PET/CT. The treatment plan
of our patients was modiﬁed 18% of the time. In this subset
of patients, preoperative PET/CT should be considered as
part of the staging workup, and further studies should be
performed to validate our ﬁndings.
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